Tamtam Try Tamtam free
Jazz Pharmaceuticals logo

Jazz Pharmaceuticals account plan

developing novel medicines globally

At a glance

Jazz Pharmaceuticals is a Dublin-based rare disease biopharma (sleep, epilepsy, oncology): $4,267.6 million 2025 revenue, about 2,890 employees.

Jazz Pharmaceuticals plc is a Dublin-headquartered biopharmaceutical company focused on rare disease, with marketed medicines in rare sleep disorders (Xywav, Xyrem), rare epilepsies (Epidiolex/Epidyolex) and rare cancers (Ziihera, Modeyso, Zepzelca, Rylaze, Vyxeos, Defitelio). It has direct commercial operations in the U.S., Europe, Australia and Canada and manufactures in Ireland, the U.K. and Italy; U.S. revenues were $3,831.6 million of the 2025 total. FY2025 total revenues were $4,267.6 million (+5%) with a net loss of $356.1 million, driven by acquired IPR&D and litigation settlements. It employed approximately 2,890 people at 31 December 2025, about 53% in the U.S.; Renee D. Gala is President and CEO.

Business units

Strategic priorities

Ziihera launch in first-line GEA
FDA approval on 25 August 2026 in first-line HER2-positive GEA, targeting 3,000 to 4,000 U.S. patients a year; Jazz puts Ziihera's peak sales potential at $3 billion to $5 billion.
Revenue diversification away from oxybates
Xyrem plus high-sodium oxybate AG royalty revenue fell from 74% of total revenue in 2020 to 8% in 2025, with growth now driven by Modeyso, Ziihera and Epidiolex.
Rare disease business development
Jazz looks at licensing, structured deals and outright M&A in rare disease; it acquired Chimerix in 2025 and Actio for $820 million in 2026.
Defending Xywav
Management expects Xywav to remain foundational across NT1, NT2 and idiopathic hypersomnia, backed by Orange Book-listed patents to 2033 and 2037 and an IH patent to 2041.
Advancing the late-stage pipeline
Phase 3 trials for zanidatamab in breast cancer (EmpowHER-BC-303) and dordaviprone in diffuse glioma (ACTION, readout expected in 1H27), plus Jazz's own orexin 2 receptor agonist JZP269.

Latest results

In Q3 2026 Jazz reported record total revenues of $1,243.0 million, up 10% from $1,126.1 million, and $3,520.2 million for nine months. Xywav grew 12% and oncology sales reached $387.1 million, while Epidiolex/Epidyolex slipped 2%. The GAAP net loss was $483.4 million after $754.2 million of acquired IPR&D from the Actio acquisition. Full-year 2026 total revenue guidance was raised to $4,775-4,850 million from $4,600-4,750 million in August, nearly 13% growth at the midpoint.

Investments and deals

Actio acquisition
Closed in September 2026 for $820 million, adding ABS-1230 (JZP6979), a potential first-in-class therapy for KCNT1-related epilepsy.
Chimerix acquisition
Acquired in 2025 for $944.2 million, bringing Modeyso, which reached about $200 million of sales and 725 patients since its August 2025 launch.
Saniona licence
JZP053 (Kv7.2/Kv7.3 activator) licensed in August 2025 for $42.5 million upfront.
Financing and buybacks
A $1.25 billion private placement of 1.875% exchangeable notes due 2032, $225 million of share repurchases, a new $500 million programme approved in October 2026, and the Term Loan B extended to May 2033.

Challenges and risks

Oxybate competition
Lumryz, authorized generics, approved high-sodium generics, Xywav ANDA filers and orexin 2 receptor agonists in development at several companies threaten the sleep franchise.
Drug pricing reform
IRA Medicare negotiation, Medicaid rebate changes and CMS most-favoured-nation models, plus uncertainty on MFN pricing for Ziihera outside the U.S.
Tariffs on manufacturing
Tariffs on pharmaceutical imports could hit margins as early as fiscal 2026 given manufacturing in Ireland, the U.K. and Italy; Jazz increased U.S. inventory in anticipation.
Debt load
Long-term debt principal was $5.6 billion at 30 September 2026 against $2.9 billion of cash, cash equivalents and investments.
Oncology competition
Amgen's IMDELLTRA is expected to be a headwind for Zepzelca in 2027, and Modeyso faces a more measured revenue pace in the near term.

What leadership says

“was a defining milestone for Jazz, establishing an important new source of growth”

Renee Gala, President and Chief Executive Officer · Q3 2026 earnings call, 2 November 2026, on the Ziihera first-line GEA approval

“As we enter 2027, we have clear priorities, the financial strength to invest behind them and a strong track record of execution.”

Renee Gala, President and Chief Executive Officer · Q3 2026 earnings call, 2 November 2026

“We are highly engaged on the BD front, and I do expect us to have deals announced over the course of this year.”

Renee Gala, President and Chief Executive Officer · Q1 2026 earnings call, 5 May 2026

Where a supplier can help

Community oncology launch support
Tied to the Ziihera launch: the commercial strategy broadens reach to community accounts, where about 80% of new ordering accounts sit, so field enablement, HCP engagement and data services are relevant.
Clinical trial services
Tied to the late-stage pipeline: CRO, site and data services fit Phase 3 trials such as EmpowHER-BC-303 and ACTION and the registrational KYRON trial.
Supply chain resilience
Tied to the tariff challenge: manufacturing, inventory and trade-compliance offers address a stated margin risk on Irish, U.K. and Italian production.
Patient support programmes
Tied to defending Xywav: management credits JazzCares support services and the REMS for limiting generic erosion, so patient services and adherence tools fit.
Business development diligence
Tied to rare disease business development: advisory, diligence and integration support match an active deal strategy after Chimerix and Actio.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Jazz Pharmaceuticals?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Jazz Pharmaceuticals

What does Jazz Pharmaceuticals do?

Jazz develops and sells medicines for rare diseases in sleep disorders, epilepsy and oncology, including Xywav, Epidiolex, Ziihera and Modeyso.

What was Jazz Pharmaceuticals' revenue in 2025?

Total revenues were $4,267.6 million in 2025, up 5%; 2026 guidance is $4,775-4,850 million.

How many employees does Jazz Pharmaceuticals have?

Approximately 2,890 at 31 December 2025, about 53% in the U.S.; more than 740 support R&D.

Who leads Jazz Pharmaceuticals?

Renee D. Gala is President and CEO and Philip L. Johnson is CFO.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)